Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: rofi e. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. Del Re M, et al. Among authors: rofi e. Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10. Eur Urol. 2017. PMID: 27733296
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R. Del Re M, et al. Among authors: rofi e. Crit Rev Oncol Hematol. 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002. Epub 2018 Mar 6. Crit Rev Oncol Hematol. 2018. PMID: 29650277 Review.
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
Pasqualetti F, Restante G, Gonnelli A, Rofi E, Molinari A, Crucitta S, Paiar F, Rudà R, Danesi R, Soffietti R, Del Re M. Pasqualetti F, et al. Among authors: rofi e. Neuro Oncol. 2019 Dec 17;21(12):1610-1611. doi: 10.1093/neuonc/noz157. Neuro Oncol. 2019. PMID: 31504796 Free PMC article. No abstract available.
Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Del Re M, et al. Among authors: rofi e. Pharmacogenomics. 2016 Dec;17(18):1967-1969. doi: 10.2217/pgs-2016-0162. Epub 2016 Nov 24. Pharmacogenomics. 2016. PMID: 27883289 Free article. No abstract available.
Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Del Re M, et al. Among authors: rofi e. Pharmacogenomics. 2017 Jun;18(8):755-756. doi: 10.2217/pgs-2017-0065. Epub 2017 Jun 8. Pharmacogenomics. 2017. PMID: 28593824
Letter in regards to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? ...
Letter in regards to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? …
34 results